መነሻ › ክሮኒክ ሊምፎሳይቲክ ሉኬሚያ › ማሳቹሴትስ

በማሳቹሴትስ ለክሮኒክ ሊምፎሳይቲክ ሉኬሚያ የሚደረጉ ክሊኒካዊ ጥናቶች

ለክሮኒክ ሊምፎሳይቲክ ሉኬሚያ የሚደረጉ 33 ጥናቶች በማሳቹሴትስ ባሉ ቦታዎች ተሳታፊዎችን እየፈለጉ ነው።

በማሳቹሴትስ ውስጥ ያሉ ከተሞች

Official study text (English)

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

Dana-Farber Cancer Institute, Boston

ተሳታዮችን በመፈለግ ላይደረጃ 3

እድሜ 65 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2026 · NCT07321652

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

Tufts Medical Center, Boston
Dana-Farber Cancer Institute, Boston
Tufts Medical Center Cancer Center Stoneham, Stoneham

ተሳታዮችን በመፈለግ ላይደረጃ 3

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ30 ሴፕቴ 2026 · NCT04269902

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

Beth Israel Deaconess Medical Center (Bidmc), Boston
Dana Farber Cancer Institute, Boston

ተሳታዮችን በመፈለግ ላይደረጃ 3

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ28 ሴፕቴ 2026 · NCT06943872

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

Dana Farber Cancer Institute, Boston

ተሳታዮችን በመፈለግ ላይደረጃ 1/2

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ28 ሴፕቴ 2026 · NCT05006716

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

Dana Farber Cancer Institute, Boston

ተሳታዮችን በመፈለግ ላይደረጃ 3

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ28 ሴፕቴ 2026 · NCT07277231

A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

Dana Farber Cancer Institute, Boston

ተሳታዮችን በመፈለግ ላይደረጃ 1/2

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ28 ሴፕቴ 2026 · NCT06697184

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Dana Farber Cancer Institute, Boston

ተሳታዮችን በመፈለግ ላይደረጃ 3

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ28 ሴፕቴ 2026 · NCT06973187

Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia

Dana-Farber Cancer Institute, Boston

ተሳታዮችን በመፈለግ ላይደረጃ 2

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ11 ሴፕቴ 2026 · NCT07061951

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

Research Site, Boston

ተሳታዮችን በመፈለግ ላይደረጃ 1/2

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ8 ሴፕቴ 2026 · NCT06564038

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

Tufts Medical Center, Boston

ተሳታዮችን በመፈለግ ላይደረጃ 1

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ8 ሴፕቴ 2026 · NCT03666000

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

Massachusetts General Hospital, Boston

ተሳታዮችን በመፈለግ ላይደረጃ 1/2

እድሜ 12 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ3 ሴፕቴ 2026 · NCT04588922

Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy

Brigham and Women's Hospital, Boston
Dana-Farber Cancer Institute, Boston

ተሳታዮችን በመፈለግ ላይደረጃ 4

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ11 ኦገስ 2026 · NCT07426484

Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL

Massachusetts General Hospital, Boston

ተሳታዮችን በመፈለግ ላይደረጃ 2

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ11 ኦገስ 2026 · NCT06849713

Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab

Research Site, Boston

ተሳታዮችን በመፈለግ ላይደረጃ 2

እድሜ ከ18 እስከ 130 · ሁሉም ጾታዎች · የተሻሻለው በ6 ኦገስ 2026 · NCT07024706

A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

Brigham and Women's Hospital, Boston

ተሳታዮችን በመፈለግ ላይደረጃ 1ጤናማ ተሳታዮች ይቀበላሉ

እድሜ ከ18 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ28 ጁላይ 2026 · NCT07020533

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Boston Medical Center, Boston

ተሳታዮችን በመፈለግ ላይደረጃ 2

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ19 ሜይ 2026 · NCT06588478

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

Dana-Farber Cancer Institute, Boston
Dana Farber Cancer Institute at St. Elizabeth's, Brighton
Dana Farber Cancer Institute at Merrimack Valley, Methuen
እና 2 ተጨማሪ

ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ7 ሜይ 2026 · NCT02269592

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Dana Farber Cancer Institute, Boston

ተሳታዮችን በመፈለግ ላይደረጃ 1

እድሜ 13 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ5 ሜይ 2026 · NCT04771572

Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies

Dana-Farber Cancer Institute, Boston

ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ24 ኤፕሪ 2026 · NCT00131014

Understanding Chronic Lymphocytic Leukemia

Dana Farber Cancer Institute, Boston

ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ24 ኤፕሪ 2026 · NCT04028531

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

UMass Memorial Medical Center /ID# 270023, Worcester

ተሳታዮችን በመፈለግ ላይደረጃ 3

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ9 ኤፕሪ 2026 · NCT06428019

CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

DFCI/BWH Brigham and Women's Hospital, Boston

ተሳታዮችን በመፈለግ ላይደረጃ 2ጤናማ ተሳታዮች ይቀበላሉ

እድሜ ከ18 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ10 ማርች 2026 · NCT06059391

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Dana-Farber Cancer Institute, Boston

ተሳታዮችን በመፈለግ ላይደረጃ 4

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ2 ማርች 2026 · NCT06876662

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

Dana-Farber Cancer Institute, Boston

ተሳታዮችን በመፈለግ ላይደረጃ 4

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ2 ማርች 2026 · NCT06876649

Study of SGR-1505 in Mature B-Cell Neoplasms

Beth Israel Deaconess Medical Center, Boston

ተሳታዮችን በመፈለግ ላይደረጃ 1

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ13 ፌብሩ 2026 · NCT05544019

Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)

Dana-Farber Cancer Institute, Boston

ተሳታዮችን በመፈለግ ላይደረጃ 1/2

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ11 ፌብሩ 2026 · NCT06644183

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

Dana-Farber Cancer Institute /ID# 230061, Boston

ተሳታዮችን በመፈለግ ላይደረጃ 2

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ9 ፌብሩ 2026 · NCT04895436

Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia

Beth Israel Deaconess Medical Center, Boston
Brigham & Women's Hospital, Boston
Dana-Farber Cancer Institute, Boston

ተሳታዮችን በመፈለግ ላይደረጃ 2

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ21 ጃንዩ 2026 · NCT06333262

Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

Brigham and Women's Hospital, Boston
Dana Farber Cancer Institute, Boston

ተሳታዮችን በመፈለግ ላይደረጃ 2

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ7 ጃንዩ 2026 · NCT06043674

Mosunetuzumab for CLL MRD Clearance

Brigham & Women's Hospital, Boston
Dana-Farber Cancer Institute, Boston

ተሳታዮችን በመፈለግ ላይደረጃ 1/2

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ15 ዲሴም 2025 · NCT07052695

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

University of Massachusetts Memorial Medical Center, Worcester

ተሳታዮችን በመፈለግ ላይደረጃ 1

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ10 ዲሴም 2025 · NCT05602363

Zanubrutinib and Venetoclax in CLL (ZANU-VEN)

Beth Israel Deaconess Medical Center, Boston
Dana-Farber Cancer Institute, Boston
South Shore Hospital, South Weymouth

ተሳታዮችን በመፈለግ ላይደረጃ 2

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ5 ዲሴም 2025 · NCT05168930

CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia

Dana-Farber Cancer Institute, Boston

ተሳታዮችን በመፈለግ ላይደረጃ 1

እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ17 ጁላይ 2025 · NCT04704323

ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ5 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።